Amorphous nanosilicas induce consumptive coagulopathy after systemic exposure

We previously reported that well-dispersed amorphous nanosilicas with particle size 70 nm (nSP70) penetrate skin and produce systemic exposure after topical application. These findings underscore the need to examine biological effects after systemic exposure to nanosilicas. The present study was designed to examine the biological effects. BALB/c mice were intravenously injected with amorphous nanosilicas of sizes 70, 100, 300, 1000 nm and then assessed for survival, blood biochemistry, and coagulation. As a result, injection of nSP70 caused fatal toxicity, liver damage, and platelet depletion, suggesting that nSP70 caused consumptive coagulopathy. Additionally, nSP70 exerts procoagulant activity in vitro associated with an increase in specific surface area, which increases as diameter reduces. In contrast, nSP70-mediated procoagulant activity was absent in factor XII-deficient plasma. Collectively, we revealed that interaction between nSP70 and intrinsic coagulation factors such as factor XII, were deeply related to nSP70-induced harmful effects. In other words, it is suggested that if interaction between nSP70 and coagulation factors can be suppressed, nSP70-induced harmful effects may be avoided. These results would provide useful information for ensuring the safety of nanomaterials (NMs) and open new frontiers in biological fields by the use of NMs.

[1]  L. L. Miller,et al.  SYNTHESIS OF ALL PLASMA PROTEIN FRACTIONS EXCEPT GAMMA GLOBULINS BY THE LIVER , 1954, The Journal of experimental medicine.

[2]  J. Hoogmartens,et al.  Controlled release of chlorhexidine from amorphous microporous silica. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Yasuo Yoshioka,et al.  Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. , 2011, Nature nanotechnology.

[4]  E. Vogler,et al.  Contact activation of the plasma coagulation cascade. III. Biophysical aspects of thrombin-binding anticoagulants. , 1998, Journal of biomedical materials research.

[5]  R. Stafford,et al.  Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Pepys,et al.  Human plasma fibrinogen is synthesized in the liver. , 2007, Blood.

[7]  E. Stachowiak,et al.  Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Watson,et al.  THE DOMINANT ROLE OF THE LIVER IN PLASMA PROTEIN SYNTHESIS , 1951, The Journal of experimental medicine.

[9]  Y. Yoshioka,et al.  Systemic distribution, nuclear entry and cytotoxicity of amorphous nanosilica following topical application. , 2011, Biomaterials.

[10]  J. Ilan,et al.  Hepatocytes express blood coagulation factor XII (Hageman factor). , 1990, The Journal of laboratory and clinical medicine.

[11]  J. Tsuruta,et al.  Immunohistochemical studies on synthesis and distribution of Hageman factor and kininogen. , 1986, Advances in Experimental Medicine and Biology.

[12]  J. Griffin,et al.  The biochemistry and pathophysiology of the contact system of plasma. , 1982, Advances in immunology.

[13]  C. S. Sipaut,et al.  Size-dependent physicochemical and optical properties of silica nanoparticles , 2009 .

[14]  Fabio Cerignoli,et al.  Quantum dot-doped silica nanoparticles as probes for targeting of T-lymphocytes , 2007, International journal of nanomedicine.

[15]  W J Brittain,et al.  Contact activation of the plasma coagulation cascade. I. Procoagulant surface chemistry and energy. , 1995, Journal of biomedical materials research.

[16]  Mark R Wiesner,et al.  Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. , 2006, Nano letters.

[17]  Michael V Sefton,et al.  Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. , 2004, Biomaterials.

[18]  Y. Yoshioka,et al.  Effect of surface properties of silica nanoparticles on their cytotoxicity and cellular distribution in murine macrophages , 2011, Nanoscale research letters.

[19]  A. Bloom.  The contact phase of coagulation in the presence of heparin , 1962, Journal of clinical pathology.

[20]  S. Philippou,et al.  Health hazards due to the inhalation of amorphous silica , 2001, Archives of Toxicology.

[21]  Karluss Thomas,et al.  Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  Tymish Y. Ohulchanskyy,et al.  Optical tracking of organically modified silica nanoparticles as DNA carriers: a nonviral, nanomedicine approach for gene delivery. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Margolis,et al.  The Role of Hageman Factor in the Initiation of Blood Coagulation , 1959, British journal of haematology.

[24]  T. Xia,et al.  Toxic Potential of Materials at the Nanolevel , 2006, Science.

[25]  E. Vogler,et al.  Procoagulant stimulus processing by the intrinsic pathway of blood plasma coagulation. , 2005, Biomaterials.

[26]  A. Schmaier,et al.  Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. , 1997, Blood.

[27]  Toshiro Hirai,et al.  Amorphous nanosilica induce endocytosis-dependent ROS generation and DNA damage in human keratinocytes , 2011, Particle and Fibre Toxicology.

[28]  W. Brittain,et al.  Contact activation of the plasma coagulation cascade. II. Protein adsorption to procoagulant surfaces. , 1995, Journal of biomedical materials research.